← All trials
NCT03571737
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 23, 2018
- Primary completion
- Dec 30, 2018
- Completion date
- Jan 30, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 180
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- East Carolina UniversityLead sponsor
- East Carolina UniversityReponsible party - principal investigator
- East Carolina UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.